gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblatomas, and various head and neck tumours; leukaemias and lymphoid malignancies, other disorders such as neuronal, glial, astrocytal, hypothalamic and other gliandular, macrophagal, epithelial, stromal and blastocoelic disorders, and inflammatory, angiogenic and immunologic disorders. The present sequence represents human p50 which is given in the exemplification of the present Sequence 406 AA;

នួននួននួននួន

δ Matches Query Match Best Local (30; Similarity EVEKIKTTVKESATEEKLTPVLLAKQLAAL 30 Conservative 100.0%; , , Score 138; DB 5; Pred. No. 4.3e-11; Mismatches 0 Length 406; Indels 0; Gaps

0

밁

121 EVEKIKTTVKESATEEKLTPVLLAKQLAAL 150

AAB58968 standard;

protein;

465

ovarian cancer associated antigen protein sequence SEQ ID (first entry)

Breast and

Human; breast cancer; ovarian cancer; cytostatic; immunosuppressive; nootropic; neurpprotective; antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer; vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic; cardiant; immune disorder; Addison's disease; allergy; autoimmune haemolytic anaemia; autoimmune thyroiditis; diabetes mellitus; Crohn's disease; multiple sclerosis; rheumatoid arthritis; ulcerative colitis; cardiovascular disorder; wound healing; neurological disease.

Homo sapiens.

WO200055173-A1.

08-MAR-2000; 2000WO-US005881.

12-MAR-1999; 99US-0124270P

(HUMA-) HUMAN GENOME

Rosen CA,

2000-611515/58. AAF21871.

New human breast and ovarian cancer associated gene sequences and the polypeptides encoded by these genes, useful in the prevention, treatment and diagnosis of cancer, immune disorders, cardiovascular disorders and neurological diseases. treatment

Claim 11; Page 1126-1128; 1299pp; English.

Sequences AAF21614 - AAF22031 represent DNA sequences encoding human proteins AAB58711 - AAB59128. The DNA and protein sequences are associated with breast and ovarian cancer. Included in the invention are sequences AAF22032 - AAF22040 and AAB59129 which are used in the sequences AAF22032 - AAF22040 and AAB59129 which are used in the invention and characterisation of the DNA and protein sequences of the invention. The breast and ovarian cancer associated DNA, protein, agonist or antagonist sequences exhibit cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral; antiallergic; hepatotropic; antidiabetic; antificial, artistic or district in the control of the c antifungal; antiparasitic

```
និន្និនិន្និនិន្និនិង
                                                                           protein sequences are used in the diagnosis of cancer, particularly breast and ovarian cancer. The nucleic acid sequences, proteins, agonists and agonists may also be used in the diagnosis, prevention and treatment of immune disorders e.g. Addison's disease, allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis, cardiovascular disorders such as myocardial ischaemias; wound healing; neurological diseases such as cerebral anoxia and epilepsy; and
                                                         infectious diseases
465 AA;
```

Query Match Best Local ! Matches 30; Similarity Conservative 100.0%; 0 Score 138; DB 3 Pred. No. 5e-11; Mismatches DB 3; 0 Length 465; Indels <u>,</u> Gaps

0

180 -EVEKIKTTVKESATEEKLTPVLLAKQLAAL 209 EVEKIKTTVKESATEEKLTPVLLAKQLAAL 30

밁 S

ABP53019 standard; protein; 183

05-NOV-2002

(first entry)

Mouse p50 amino acid sequence SEQ ID NO:54.

Cellular proliferation inhibition; cytostatic; antiinflammatory; cancer;

glial disorder; astrocytal disorder; hypothalamic disorder; inflammatory; glandular disorder; macrophagal disorder; epithelial disorder; stromal disorder; blastocoelic disorder; angiogenic disorder; p50 inhibitor; dynamitin inhibitor; gene therapy; tumour; carcinoma; sarcoma; glioblatoma; leukaemia; lymphoid malignancy; neuronal disorder;

Mus musculus.

immunologic disorder.

WO200264779-A2

22-AUG-2002

21-JAN-2002; 2002WO-US001708.

14-FEB-2001; 2001US-00782816.

(REGC) UNIV CALIFORNIA

Sharp DJ, Rogers GC,

WPI;

New peptide inhibitors of p50/dynamitin useful for treating cancer by inhibiting cellular proliferation, e.g. benign or malignant tumors, leukemia and lymphoid malignancies, or inflammatory, angiogenic and immunologic disorders

Disclosure; Fig 2; 55pp; English.

The present invention describes an isolated peptide (I) comprising or having at least 90% identity to (P1) or (P2). Where (P1) and (P2) are the sequences given in ABP52966 and ABP52967 and can have C-terminal and N-terminal extensions. (I) have cytostatic and antiinflammatory activities and can be used as 950/dynamitin inhibitors and in gene therapy. The peptides, nucleic acid molecules and methods from the present invention are useful for treating cancer by inhibiting cellular proliferation, such as benign or malignant tumours (renal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblatomas, and various head and neck tumours); leukaemias and lymphoid malignancies, other disorders such